Thank you to everyone who contributed to this achievement, especially our partners Ghana Health Service | Kenya Medical Research Institute (KEMRI) | Chemo | Barcelona Institute for Global Health (ISGlobal) | Bridges to Development | Wellcome Sanger Institute
#NTDs #WorldNTDday #globalhealth
This marks a significant step forward in our mission to make impactful treatments and make them more accessible. We began 2025 with the adoption of a positive scientific opinion on the FDC by the EMA, and we brought the year to a close with Ghana's approval, a first for a national agency.
Our vision for a better tool for parasite control is becoming a reality. Ghana FDA has approved our fixed-dose coformulation of ivermectin and albendazole.
From the start, the STOP projects have aimed to advance an innovative tool to fight STH infections. Now, with our fixed-dose coformulation in Phase IV trials, we’re closer than ever to delivering endemic countries with a new medicine for their NTD control goals!
🌍 Learn more 👉 stop2030.org/project/
Over 20 countries run national #deworming programmes 🌍These efforts are primarily concentrated in Africa, with several countries targeting millions of children to control STH infections. From Kenya to Ethiopia, these programmes are vital to improving children's healthy development.
Check out our latest interview! 💬 Our coordinator Dr Alejandro Krolewiecki was at Contagion Live talking about our co-formulation and the opportunities it can bring to endemic countries! Watch the whole interview here
Combining #ivermectin and albendazole outperforms albendazole monotherapy for Trichuris and hookworm, according to a new meta-analysis. The combination shows higher effectiveness against more species while maintaining a similar safety profile. journals.lww.com/md-journal/f...
We are incredibly proud to be highlighted as one of the projects in this story about EDCTP and its 20-year anniversary.
Global Health EDCTP3 embodies what public-private collaboration should be, and enables us to walk the path from research to results.
sciencebusiness.net/news/edctp-t...
That’s why we work in advancing the fixed-dose combination of ivermectin & albendazole, a medicine that targets all STH species considered by WHO while maintaining the simple one-tablet-per-person strategy
Do we need a new approach to STH treatment?
❌ Current treatment used in mass drug administration shows poor efficacy against some species.
⚠️ Using only one drug type increases the risk of resistance emergence—a major challenge in infectious disease control.
While albendazole showed strong efficacy against hookworm (94.1% egg reduction), it performed poorly against Trichuris trichiura (just 31%).
This highlights the urgent need for updated treatment approaches that are effective across all STH species.
Albendazole monotherapy has been the standard for mass drug administration campaigns to control soil-transmitted helminths (STHs) for over a decade — but it’s no longer enough.
Take this recent study from Ethiopia 👇
Since then, several studies, clinical trials, and partnerships have shaped the development of our fixed-dose combination of #ivermectin & #albendazole. Want to see how far we’ve come?
📖 Explore the full scientific timeline here 👉 stop2030.org/publications/
The results of over a decade of progress.
Our journey for a better treatment for soil-transmitted helminths started in 2010, with a pilot project in Northern Argentina.
This effort, carried out by the STOP2030 Consortium, aims to improve how diseases affecting more than 1.5 billion people are tackled, and to help endemic countries reach their control targets.
Alejandro Krolewiecki, our PI, will give a pitch on the innovations behind the combination of these two drugs: a new dosing strategy that simplifies logistics, enabling the control of more species with equal or lower effort, all in a one-per-person tablet that dissolves on contact with saliva.
Today we’re presenting our fixed-dose co-formulation of ivermectin and albendazole (FDC) at the Innovation Fair 2025 in Brussels — an event that brings together innovation ecosystems from Europe, Africa, and the Mediterranean.
A glimpse into the new funding models for #NTDs R&D 📊 As funding drops, agencies and governments are exploring new approaches to ensure sustainable support for innovation and disease control. Read it here www.devex.com/news/sponsor...
Improve #NTD programs through social and behavioural change. The NTD NGO Network has released a quick guide to help organisations develop effective, sustainable, and context-appropriate strategies for #NTDcontrol and elimination.
Check it out here: www.ntd-ngonetwork.org/sites/nnn/fi...
The REALISE clinical trial is live! 🎉
Our teams in Kenya and Ghana have kicked off fieldwork for our pivotal study on the ivermectin/albendazole FDC.
20,000 children will take part to help shape the future of NTD control. 🌍💊
Read more 👉 stop2030.org/the-realise-...
We’ve wrapped up over a decade of research into three materials
🔬 A look back at our 10+ year journey
🎯 The benefits of our age-based fixed ivermectin dosing strategy
💊 The results of the pivotal clinical trial evaluating the safety and efficacy of our co-formulation
stop2030.org/resources/
To improve the lives and health of affected communities, a new treatment needs to be accepted, accessible and effectively implemented. That is why we work to gather extra evidence beyond safety and efficacy. Discover more on our website stop2030.org
Our fixed-dose tablet combines two key anthelmintic drugs to control soil-transmitted helminths 👇
💊 #Albendazole, which blocks the worms’ ability to absorb glucose
💊 And #ivermectin, which paralyses and kills the worms
By combining them, we reduce the chances of resistance emergence!
#NTDs
Under the REALISE study, we aim to treat ~20,000 people in Ghana and Kenya, thanks to our partners from the Ghana Health Service and KEMRI. The evidence we obtain will be crucial to advancing the FDC and making it available to countries around the world.
Patients in several schools have started receiving treatment, either the FDC or (in the control group) single-dose albendazole. Several years of collaborative work are behind this significant moment for our Consortium.
The REALISE study, our clinical trial to evaluate the safety in large populations of our fixed-dose coformulation of ivermectin and albendazole (FDC), has reached an important milestone.
